---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-009570"
form_type: "8-K"
ticker: "IMNN"
cik: "0000749647"
company_name: "Imunon, Inc."
filed_at: "2025-05-12T23:59:59+00:00"
generated_at: "2026-05-22T00:55:27.460711+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Imunon Q1 net loss $4.1M; cash only through late Q2 2025; Phase 3 ovarian cancer trial initiated

## Summary
- Net loss $4.1M ($0.28 per share) vs $4.9M ($0.52 per share) in Q1 2024; operating expenses down 18%.
- Cash and equivalents $2.9M as of 2025-03-31; company expects funding into late Q2 2025 only.
- First trial site initiated for Phase 3 OVATION 3 study of IMNN-001 in advanced ovarian cancer.
- Abstract for OVATION 2 updated survival analysis accepted for oral presentation at 2025 ASCO Annual Meeting.
- Appointed Douglas V. Faller, M.D., Ph.D., as Chief Medical Officer effective 2025-02-18.

## SEC filing metadata
- accession: 0001641172-25-009570
- form_type: 8-K
- ticker: IMNN
- cik: 0000749647
- company_name: Imunon, Inc.
- filed_at: 2025-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/749647/000164117225009570/0001641172-25-009570-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/749647/000164117225009570/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-009570
- JSON: https://secwatch.observer/filing/0001641172-25-009570.json
- Plain text: https://secwatch.observer/filing/0001641172-25-009570.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.